article thumbnail

The Case for Procurement Transparency

Bill of Health

By Tara Davis and Nicola Soekoe In January 2021, the Director General of the World Health Organization (WHO) observed that the world was on the brink of a “catastrophic moral failure” if wealthier nations did not ensure the equitable distribution of COVID-19 vaccines. Impact of the judgment: what have records disclosed shown?

article thumbnail

COVID-19 Showcased Failed Global Cooperation

Bill of Health

Global solidarity requires cooperation between governments, while national solidarity involves cooperation within a state to address common challenges and achieve shared goals. Solidarity operates at two intersecting levels. That has created deep inequities in access to health products that can save lives.

COVID-19 299
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

No Take-Backs: Moderna’s Attempt to Renege on its Vaccine Patent Pledge

Bill of Health

On October 8, 2020, Moderna, the maker of one of the first mRNA-based vaccines for COVID-19 and the recipient of billions of dollars of U.S. government funding, announced that it felt “a special obligation … to use our resources to bring this pandemic to an end as quickly as possible.” By Jorge L.

article thumbnail

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

Bill of Health

Such a provision could prevent the public from paying twice for publicly-funded medical products—first through their taxes subsidizing government funded research and development, and second to procure the product in an inflated U.S. pharmaceutical market. Moreover, the NASDAQ Biotechnology Index increased by 374% from 1995 to 2000.

COVID-19 205
article thumbnail

The Remarkable Rise of Pharma’s Reputation in the Pandemic

Health Populi

The reputation of the pharmaceutical industry gained a “whopping” 30 points between January 2020 and February 2021, based on the latest Harris Poll in their research into industries’ reputations. The study was written up by Beth Snyder Bulik in FiercePharma.

COVID-19 154